Exogenous hydrogen sulfide (H2S) reduces blood pressure and prevents the progression of diabetic nephropathy in spontaneously hypertensive rats.
The coexistence of hypertension and diabetes results in the rapid development of nephropathy. Hydrogen sulfide (H2S) is claimed to control the vascular and renal functions. This study tested the hypothesis that exogenous H2S lowers the blood pressure and decreases the progression of nephropathy in spontaneously hypertensive rats (SHR) that were diabetic. Eighteen SHR were divided into three groups: SHR, SHR diabetic, and SHR diabetic treated with a group of Wistar-Kyoto rats serving as normotensive nondiabetic control. Diabetes was induced with streptozotocin (STZ) in two groups and one diabetic group received sodium hydrosulfide (NaHS), a H2S donor for 5 weeks. Blood pressure was measured in conscious and anesthetized states and renal cortical blood perfusion in acute studies. Plasma and urinary H2S levels, creatinine concentrations, and electrolytes were measured on three different occasions throughout the 35-day period. Diabetic SHR had higher blood pressure, lower plasma and urinary H2S levels, and renal dysfunction as evidenced by increased plasma creatinine, creatinine clearance, and decreased urinary sodium-to-potassium ratio and renal cortical blood perfusion. NaHS reduced blood pressure, increased H2S levels in plasma and urinary excretion, and reversed the STZ-induced renal dysfunction. The findings of this study suggest that the administration of exogenous H2S lowers the blood pressure and confers protection against the progression of STZ-induced nephropathy in SHR.
Department of Physiology, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia. fa09_PHA116@student.usm.my
Fiaz Ud Din
FU
Ahmad
Munavvar Abdul
MA
Sattar
Hassaan Anwer
HA
Rathore
Mohammed Hadi
MH
Abdullah
Samual
S
Tan
Nor Azizan
NA
Abdullah
Edward James
EJ
Johns
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D003928:Diabetic Nephropathies / Q000209:etiology / Q000517:prevention & control*; D018450:Disease Progression; D006862:Hydrogen Sulfide / Q000494:pharmacology* / Q000627:therapeutic use*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY
D006862:Hydrogen Sulfide